Company / Profit Margin
Travere Therapeutics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-5.2%
FY2025
5-year range
-254.4% / -5.2%
FY2021-FY2025
Trend
+96.2%
vs FY2024
Sector context
#66 of 146
Health Care
What the data says
At -5.2%, Travere Therapeutics, Inc.'s profit margin ranks #66 of 146 in the Health Care sector. Profit Margin has fluctuated over the past 10 years, ranging from -393.4% in FY2016 to 117.4% in FY2017.
Based on SEC 10-K filings.
-5.2% in FY2025 with a 5-year CAGR of +57.3%.
Improved from -76.7% to -5.2% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +249.2pp
- 5-Year Change
- +57.3pp
- 10-Year Change
- -
Sector benchmark
#66 of 146 in Health CareTop 45% of 146This company -5.2% Sector average -796.3%
▼
+99.3% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 96.2% year-over-year.
- Currently 791.1pp above the Health Care sector average.
- Peak profit margin was recorded in FY2017.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -5.2% | +96.2% |
| FY2024 | -137.9% | -79.8% |
| FY2023 | -76.7% | +69.9% |
| FY2022 | -254.4% | -204.6% |
| FY2021 | -83.5% | -33.6% |
| FY2020 | -62.5% | -62.2% |
| FY2019 | -38.6% | -7.5% |
| FY2018 | -35.9% | -130.6% |
| FY2017 | 117.4% | +129.8% |
| FY2016 | -393.4% | -435.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026